The Phase I proof-of-concept trial is being conducted at a single center with approximately 30 healthy male volunteers and is designed to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172.
Dr. Errol De Souza, president and CEO of Archemix, said: “We are pleased that Nuvelo has advanced NU172 into clinical trials. NU172 demonstrates the productivity of our aptamer discovery efforts and we look forward to its clinical development.”